Global Opioid Induced Constipation Drugs Market -
Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022
The latest
market report published by Credence Research “Global Opioid Induced
Constipation Drugs Market - Growth, Share, Opportunities, Competitive Analysis,
and Forecast, 2016-2022,” the opioid induced constipation drugs market was
valued at USD 1,933.2 Mn in 2015, and is expected to reach USD 2,779.24 Mn by
2022, expanding at a CAGR of 4.6% from 2016 to 2022.
Browse the full report Opioid Induced Constipation
Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and
Forecast, 2016–2022 report at http://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market
Market Insights
Alarming
growth in opioid prescription for non-cancer pain has been a phenomenal event
in the previous decade. As per the recent estimates, more than 40% of opioid
consumers experience constipation and GI symptoms as side effects of opioid
drugs. Rising pool of opioid users will lead to the growth in opioid induced
constipation (OIC) prevalence thus contributing to OIC drugs market growth. The
global opioid induced constipation drugs market was valued at USD 1,933.2 Mn in
2014 and is expected to reach USD 2,779.2 Mn by 2022 with the market growing at
a CAGR of 4.6% during 2016-2022.
Methylnaltrexone
bromide, lubiprostone and naloxegol are the three drugs currently indicated for
OIC treatment. Among these, methylnaltrexone bromide holds the largest market
size and is expected to progress with a CAGR of 2.9% during the forecast
period. Relistor from Salix Pharmaceuticals is indicated for treatment of OIC
in patients with advanced illness receiving palliative care, particularly when
standard laxative therapy proves insufficient. Lubiprostone under the brandname
Amitiza is indicated for treating OIC, where it major indication is for chronic
idiopathic constipation (CIC). Lubiprostone is expected that the segment will
take over the market share of methylnaltrexone bromide. Additionally, naloxegol
is expected to grow at highest CAGR over the forecast period. The drug is under
testing for various patient types such as pregnant women and patients less than
17 years of age. Thus, future approvals are expected to lead the market.
North America
is the dominant regional OIC drugs market through the forecast period. Early
bird approval of OIC drugs by the USFDA and high consumption of opioids in the
US are the prime growth factors for the OIC drugs market in North America. On
the other hand, Germany, UK, and Spain are the major countries setting the
market dynamics in Europe. Overall, the developed countries across the world,
predominantly North America and Europe are the key consumers of OIC drugs.
For More
Reports Related to This Category @ http://www.credenceresearch.com/industry/pharmaceuticals-market
On the basis
of prescription type the market is segmented into prescribed drugs and over the
counter or OTC drugs. Constipation is never considered as a disease but a
syndrome or a side effect; people are less likely to visit doctors to get
prescription for constipation. Thus, the OIC drugs market is dominated by over
the counter prescription with 65.87% market share in 2014. The OTC drug market
will continue to dominate the market growing at the highest CAGR of 4.9% during
2016-2022.
About Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith (Global Sales
Manager)
Address:
105 N 1st ST #429, SAN JOSE, CA 95103 US
Ph: 1-800-361-8290
No comments:
Post a Comment